Urogen Pharma (URGN) AI Stock Analysis

• Market Cap: $1.08B
• Dividend Yield: N/A
• Average Volume (3M): 1.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: 8.00%
• EPS Growth: -10.15%
• Country: US
• Employees: 234
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 46,808,890
• 10 Day Avg. Volume: 1,542,681
• 30 Day Avg. Volume: 1,225,224
• PEG Ratio: 0.22
• Price to Book (P/B): -51.87
• Price to Sales (P/S): 5.05
• P/FCF Ratio: -4.70
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 13.28
• Enterprise Value/Gross Profit: 14.95
• Enterprise Value/Ebitda: -10.54
• 1Y Price Target: $39.40
• Price Target Upside: 56.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $24.50 ▼(-2.55% Downside)

Urogen Pharma's stock score is primarily influenced by its financial challenges, despite strong technical momentum and positive earnings call highlights. The company's high leverage and negative profitability are significant risks, while promising product growth offers potential upside.

Positive Factors

FDA Approval of ZUSDURI

FDA approval of ZUSDURI opens a significant market opportunity, potentially driving long-term revenue growth and strengthening Urogen's market position in urological therapies.

Strong JELMYTO Revenue Growth

Consistent revenue growth for JELMYTO indicates strong market adoption and supports Urogen's revenue base, contributing to financial stability and future expansion.

Robust Cash Position

A strong cash position provides Urogen with the financial flexibility to invest in R&D, expand operations, and weather potential market challenges, supporting long-term growth.

Negative Factors

Reimbursement Challenges for ZUSDURI

Reimbursement challenges can hinder ZUSDURI's market penetration, affecting revenue potential and slowing the adoption of this newly approved therapy.

Increased Operating Expenses

Rising operating expenses, driven by commercial preparation, could pressure margins and profitability, limiting Urogen's ability to achieve sustainable financial performance.

High Leverage and Negative Equity

High leverage and negative equity pose financial stability risks, potentially restricting Urogen's ability to raise capital and invest in growth initiatives.

Urogen Pharma Business Overview & Revenue Model

Company Description

Urogen Pharma Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases. The company specializes in the research and development of products designed to treat conditions such as bladder cancer and other urological disorders, leveraging its proprietary technology platforms to create targeted therapies. Urogen's core products include its lead investigational therapies, which aim to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions.

How the Company Makes Money

Urogen Pharma generates revenue primarily through the commercialization of its pharmaceutical products. The company earns money by selling its approved therapies to healthcare providers, hospitals, and specialty pharmacies. Key revenue streams include product sales from its marketed therapies and potential royalties from partnerships or licensing agreements related to its drug development programs. Urogen may also engage in collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments upon achieving certain development goals, and royalties on future sales. Additionally, the company may receive funding through grants or research partnerships that support its clinical trials and development efforts.

Urogen Pharma Financial Statement Overview

Summary

Urogen Pharma shows revenue growth but struggles with profitability and financial stability. High gross profit margins are overshadowed by negative net income and high leverage, posing significant risks.

Income Statement

Urogen Pharma's income statement shows a consistent increase in revenue over the years, with a TTM revenue growth rate of 2.42%. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin remains high at 88.54% for TTM, which is a positive sign, but the persistent net losses and negative EBIT margins highlight ongoing operational challenges.

Balance Sheet

The balance sheet reveals significant financial instability, with a negative stockholders' equity and a high debt-to-equity ratio of -1.35 for TTM. This indicates that the company is heavily leveraged and may face difficulties in meeting its financial obligations. The return on equity is also negative, reflecting the company's inability to generate profits from its equity base.

Cash Flow

The cash flow statement shows negative operating and free cash flows, although there is a slight improvement in free cash flow growth at 11.82% for TTM. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from its operations to cover its net losses. The free cash flow to net income ratio is slightly above 1, suggesting some efficiency in converting net income into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	72.30M	90.40M	82.71M	64.36M	48.04M	11.80M
Gross Profit	64.22M	81.52M	73.35M	56.70M	42.88M	10.79M
EBITDA	-91.14M	-95.35M	-60.35M	-76.21M	-91.46M	-122.71M
Net Income	-114.70M	-126.87M	-102.24M	-109.78M	-110.82M	-128.48M
Balance Sheet
Total Assets	185.05M	285.71M	178.31M	135.62M	119.75M	122.00M
Cash, Cash Equivalents and Short-Term Investments	127.03M	236.69M	136.97M	99.96M	89.14M	102.02M
Total Debt	129.94M	123.39M	99.39M	99.12M	398.00K	1.50M
Total Liabilities	300.45M	294.51M	243.52M	224.98M	111.33M	25.65M
Stockholders Equity	-115.41M	-8.80M	-65.21M	-89.36M	8.41M	96.36M
Cash Flow
Free Cash Flow	-138.13M	-97.06M	-76.57M	-87.81M	-85.64M	-107.10M
Operating Cash Flow	-137.74M	-96.77M	-76.38M	-87.56M	-84.89M	-105.89M
Investing Cash Flow	94.46M	-20.61M	-953.00K	1.06M	4.07M	93.24M
Financing Cash Flow	8.67M	194.62M	116.93M	97.13M	72.32M	16.53M

Urogen Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For URGN, the sentiment is Positive. The current price of 25.14 is above the 20-day moving average (MA) of 20.18, above the 50-day MA of 18.95, and above the 200-day MA of 13.98, indicating a bullish trend. The MACD of 1.53 indicates Negative momentum. The RSI at 73.32 is Negative, neither overbought nor oversold. The STOCH value of 84.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for URGN.

Urogen Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAT	61 Neutral	$976.73M	―	―	―	460.30%	33.03%
URGN	57 Neutral	$1.08B	―	―	―	8.00%	-10.15%
ZBIO	55 Neutral	$1.37B	―	-68.33%	―	―	―
TSHA	52 Neutral	$1.07B	―	-64.93%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABUS	51 Neutral	$879.90M	―	-52.82%	―	53.23%	35.32%
GERN	47 Neutral	$740.49M	―	-29.57%	―	522.13%	62.68%

Urogen Pharma Corporate Events

UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth

UroGen Pharma Ltd., a biotechnology company, focuses on developing innovative treatments for urothelial and specialty cancers using its proprietary RTGel® technology. In its third-quarter 2025 earnings report, UroGen highlighted the successful launch of ZUSDURI, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and reported a net product revenue of $1.8 million for ZUSDURI in its first quarter on the market. The company also achieved $25.7 million in net product revenue for JELMYTO, reflecting a 13% year-over-year growth. UroGen’s financial position remains strong with $127.4 million in cash and equivalents, despite a net loss of $33.3 million for the quarter. The company is optimistic about the commercial potential of ZUSDURI, supported by strong patient demand and broad reimbursement coverage. Looking ahead, UroGen plans to submit a New Drug Application for UGN-103 in 2026, aiming for approval in 2027, and continues to advance its pipeline to deliver long-term value for patients and shareholders.

UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment

Study Overview: UroGen Pharma is conducting a Phase 3, single-arm, multicenter study to evaluate the efficacy and safety of UGN-104, a novel formulation of UGN-101, for treating patients with low-grade upper tract urothelial cancer (LG-UTUC). This study aims to provide a new therapeutic option for LG-UTUC, a condition with limited treatment alternatives, enhancing patient outcomes and expanding UroGen’s product portfolio.

UroGen Pharma’s Phase 3 Study on UGN-103: A Potential Game-Changer in Bladder Cancer Treatment

Study Overview: UroGen Pharma is conducting a Phase 3 study titled ‘A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate-risk (IR) of Recurrence.’ The study aims to assess the efficacy and safety of UGN-103 in treating patients with low-grade non-muscle invasive bladder cancer, a condition with significant recurrence risk, thereby addressing a crucial need in cancer treatment.

Urogen Pharma’s Jelmyto Registry: Real-World Insights into UTUC Treatment

Study Overview: The uTRACT Jelmyto Registry is a multicenter, prospective and retrospective registry designed to evaluate real-world experiences and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto. This study is significant as it aims to provide insights into the effectiveness and safety of Jelmyto in a real-world setting, potentially influencing treatment protocols and patient care strategies.

UroGen Pharma Shareholders Approve Key Proposals at Meeting

UroGen Pharma’s shareholders convened at the Annual Meeting to vote on several key proposals. The shareholders elected seven directors, approved an amended compensation policy, and endorsed the 2017 Amended Plan. Additionally, they approved the executive compensation and decided to hold annual advisory votes on this matter. PricewaterhouseCoopers LLP was appointed as the independent auditor until 2026.

The most recent analyst rating on (URGN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Urogen Pharma stock, see the URGN Stock Forecast page.

UroGen Pharma’s Earnings Call: Achievements and Challenges

UroGen Pharma’s recent earnings call painted a picture of both achievement and challenge. The company celebrated significant milestones, such as the FDA approval of ZUSDURI and revenue growth for JELMYTO, while also addressing hurdles like reimbursement issues and an increased net loss. Despite these challenges, UroGen’s robust financial standing and strategic initiatives for future growth contribute to a positive outlook.

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

UroGen Pharma Ltd., a biotechnology company, focuses on developing and commercializing innovative treatments for urothelial and specialty cancers, utilizing its proprietary RTGel technology for sustained drug delivery.